IRONWOOD PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-16.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2024-02-16
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-12-31 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-06-30 was -$1.43M.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2022-03-31 was $313.00K.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2023 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2022 was -$1.11M.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2021 was -$11.95M.
- IRONWOOD PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2020 was -$18.30M, a 195.05% decline from fiscal 2019.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-16 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | $0.00 derived: sum of 2 quarters · filed 2024-02-16 | -$1.43M derived: sum of 3 quarters · filed 2024-02-16 | -$1.11M 10-K · filed 2024-02-16 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.43M derived: sum of 2 quarters · filed 2022-11-03 | -$1.11M 10-Q · filed 2022-11-03 | -$7.85M derived: sum of 4 quarters · filed 2023-02-16 |
| 2022-06-30 | -$1.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.11M 10-Q · filed 2022-08-04 | -$7.85M derived: sum of 3 quarters · filed 2023-02-16 | -$11.26M derived: sum of 4 quarters · filed 2023-02-16 |
| 2022-03-31 | $313.00K 10-Q · filed 2022-05-05 | -$6.43M derived: sum of 2 quarters · filed 2023-02-16 | -$9.83M derived: sum of 3 quarters · filed 2023-02-16 | -$9.92M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-12-31 | -$6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | -$10.15M derived: sum of 2 quarters · filed 2023-02-16 | -$10.23M derived: sum of 3 quarters · filed 2023-02-16 | -$11.95M 10-K · filed 2023-02-16 |
| 2021-09-30 | -$3.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$3.49M derived: sum of 2 quarters · filed 2021-11-04 | -$5.21M 10-Q · filed 2021-11-04 | -$398.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2021-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.80M 10-Q · filed 2021-08-05 | $3.01M derived: sum of 3 quarters · filed 2022-02-18 | -$4.87M derived: sum of 4 quarters · filed 2022-02-18 |
| 2021-03-31 | -$1.72M 10-Q · filed 2021-05-06 | $3.09M derived: sum of 2 quarters · filed 2022-02-18 | -$4.79M derived: sum of 3 quarters · filed 2022-02-18 | -$4.50M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$3.07M derived: sum of 2 quarters · filed 2022-02-18 | -$2.78M derived: sum of 3 quarters · filed 2022-02-18 | -$18.30M 10-K · filed 2022-02-18 |
| 2020-09-30 | -$7.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$7.59M derived: sum of 2 quarters · filed 2020-11-05 | -$23.11M 10-Q · filed 2020-11-05 | -$3.10M derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-06-30 | $284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$15.23M 10-Q · filed 2020-08-06 | $4.77M derived: sum of 3 quarters · filed 2021-02-17 | -$15.68M derived: sum of 4 quarters · filed 2021-02-17 |
| 2020-03-31 | -$15.52M 10-Q · filed 2020-05-06 | $4.49M derived: sum of 2 quarters · filed 2021-02-17 | -$15.96M derived: sum of 3 quarters · filed 2021-02-17 | -$5.83M derived: sum of 4 quarters · filed 2021-02-17 |
| 2019-12-31 | $20.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | -$445.00K derived: sum of 2 quarters · filed 2021-02-17 | $9.69M derived: sum of 3 quarters · filed 2021-02-17 | $19.25M 10-K · filed 2021-02-17 |
| 2019-09-30 | -$20.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | -$10.32M derived: sum of 2 quarters · filed 2019-10-31 | -$754.00K 10-Q · filed 2019-10-31 | -$102.51M derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-06-30 | $10.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $19.70M 10-Q · filed 2019-07-30 | -$82.05M derived: sum of 3 quarters · filed 2020-02-13 | -$98.81M derived: sum of 4 quarters · filed 2020-02-13 |
| 2019-03-31 | $9.57M 10-Q · filed 2019-05-02 | -$92.19M derived: sum of 2 quarters · filed 2020-02-13 | -$108.94M derived: sum of 3 quarters · filed 2020-02-13 | |
| 2018-12-31 | -$101.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | -$118.51M derived: sum of 2 quarters · filed 2020-02-13 | -$67.17M 10-K · filed 2020-02-13 | |
| 2018-09-30 | -$16.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $34.59M 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | $51.34M 10-Q · filed 2018-08-06 | |||
| 2017-12-31 | -$24.33M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |